LOSS OF TELOMERIC DNA DURING AGING MAY PREDISPOSE CELLS TO CANCER (REVIEW)
The DOI matches its Crossref record.
Abstract
In normal human somatic cells, gradual shortening of telomeres may activate the complex cascade of molecular events known as cellular senescence. Experimental evidence from our laboratory suggests that cellular mortality is regulated by two separate mechanisms that we have termed mortality stage 1 (M1) and mortality stage 2 (M2). In mammary epithelial cells, the M1 mechanism involves de-regulation of p53 whereas in fibroblasts both the retinoblastoma (Rb) and p53 gene products are implicated. Cells that overcome the function of these antiproliferative proteins (M1 controls) continue to divide until a second entirely independent mechanism, M2 is induced. As somatic cells age they gradually lose telomeric sequences at the termini of their chromosomes, a process that continues during the extended lifespan period between M1 and M2. Immortal and cancer cells, as well as cells that maintain telomere length (e.g. germ cells), express telomerase, a ribonucleoprotein which maintains (stabilizes) telomere length by synthesizing TTAGGG repeats. Because normal human somatic cells and cells prior to M2 do not express telomerase, we propose that the M2 mechanism involves either the direct or indirect induction of telomerase activity. In order for cells to overcome senescence and become immortal, they must first escape the checkpoints that limit the proliferative capacity of normal cells, the MI and M2 controls (a very rare event). However, the probability of immortalization and that of tumorigenesis increases with age and we propose telomere shortening and reactivation of telomerase are important components in these processes. Once immortal, cells can then follow many pathways that result in the acquisition and progression of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Correlating telomerase activity levels with human neuroblastoma outcomes
Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M. A., & Shay, J. W. (1995) · Nature Medicine · doi:10.1038/nm0395-249 · Cited by 611
Self-citationPiatyszek, M. A., Kim, N. W., Weinrich, S. L., Hiyama, K., Hiyama, E., Wright, W. E., & Shay, J. W. (1995) · Methods in Cell Science · doi:10.1007/bf00981880 · Cited by 384
Self-citationReplicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion?
Effros, R. B., & Pawelec, G. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01079-7 · Cited by 336
Telomeres and telomerase in aging and cancer
Harley, C. (1995) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(95)80016-6 · Cited by 324
Telomeres shorten more slowly in long-lived birds and mammals than in short–lived ones
Haussmann, M. F., Winkler, D. W., O'Reilly, K. M., Huntington, C. E., Nisbet, I. C. T., & Vleck, C. M. (2003) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.2003.2385 · Cited by 288
Biology of premature ageing in survivors of cancer
Cupit-Link, M. C., Kirkland, J. L., Ness, K. K., Armstrong, G. T., Tchkonia, T., LeBrasseur, N. K., Armenian, S. H., Ruddy, K. J., & Hashmi, S. K. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000250 · Cited by 214
Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis
Miura, N., Horikawa, I., Nishimoto, A., Ohmura, H., Ito, H., Hirohashi, S., Shay, J. W., & Oshimura, M. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00329-9 · Cited by 174
Self-citationCuthbert, A. P., Bond, J., Trott, D. A., Gill, S., Broni, J., Marriott, A., Khoudoli, G., Parkinson, E. K., Cooper, C. S., & Newbold, R. F. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.37 · Cited by 114
Metadata
- Authors
- SHAY, J., WRIGHT, W., & WERBIN, H.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 1993-10-01
- Volume
- 3
- Issue
- 4
- Pages
- 559-63
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2074839476
- Cited by
- 37
- References
- 0
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.